61 citations
,
January 2019 in “American Journal of Clinical Dermatology” The cause of Frontal Fibrosing Alopecia is unclear, diagnosis involves clinical evaluation and various treatments exist, but their effectiveness is uncertain.
8 citations
,
September 2011 in “European Journal of Dermatology” Most treatments for Frontal Fibrosing Alopecia are ineffective, but early anti-inflammatory therapy may help and the condition may stabilize over time.
January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
September 2024 in “Skin Appendage Disorders” Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.
70 citations
,
April 2016 in “Experimental Dermatology” A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
2 citations
,
May 2021 in “Clinical Pharmacology in Drug Development” Clascoterone is safe for the heart, even at high doses.
April 2017 in “Leukemia research” Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
13 citations
,
January 2018 in “International Journal of Trichology” Intralesional triamcinolone injections can effectively stop frontal fibrosing alopecia with minimal side effects.
August 2025 in “JAAD International” Bicalutamide may reduce hair shedding in women but needs longer trials to confirm its effectiveness.
January 2024 in “Dermatologic Therapy” Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.
Early combination therapy can effectively regrow hair in frontal fibrosing alopecia.
23 citations
,
April 2021 in “Journal of Clinical Medicine” Frontal Fibrosing Alopecia's cause is unclear, affects mainly postmenopausal women, and current treatments focus on stopping hair loss rather than regrowth.
February 2025 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Deucravacitinib helped a man regrow hair and improve psoriasis.
155 citations
,
September 2008 in “British journal of dermatology/British journal of dermatology, Supplement” FFA is more common in postmenopausal women, can affect younger women, and may stabilize over time.
139 citations
,
November 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
14 citations
,
November 2016 in “Annals of Internal Medicine” Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.
15 citations
,
December 2009 in “PubMed” A child with eruptive vellus hair cysts showed some improvement with calcipotriene cream.
97 citations
,
January 2020 in “Advances in chronic kidney disease” Calcineurin inhibitors, used in kidney transplants, can cause a wide range of side effects including kidney damage and other health issues.
3 citations
,
September 2022 in “Journal of the American Academy of Dermatology” Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
April 2026 in “Clinical and Translational Science” Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Upadacitinib effectively treats severe alopecia areata and is safe.
2 citations
,
February 1990 in “PubMed” DDR-II hair follicle cells don't respond to 1, 25-dihydroxyvitamin D3, aiding diagnosis.
December 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Deucravacitinib helped a man regrow hair significantly.
14 citations
,
February 2013 in “PubMed” Patients treated with long-term intralesional corticosteroids for alopecia areata should be monitored for bone density changes and advised on osteoporosis prevention.
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
2 citations
,
January 2010 in “Side effects of drugs annual” Dermatological drugs and cosmetics can cause serious side effects like cancer, allergies, and heart issues.
September 2025 in “Journal of Skin and Stem Cell” The combination of calcipotriol and PRP is the most effective treatment for alopecia areata.
June 2022 in “C&EN global enterprise” The drug Olumiant is now approved to treat severe hair loss from alopecia and can also be used for some hospitalized COVID-19 patients.
1 citations
,
November 2023 in “International Journal of Dermatology” Topical calcineurin inhibitors might be safer than steroids for scarring alopecia, but more research is needed.
38 citations
,
January 2019 in “International Journal of Women's Dermatology” The document concluded that more research is needed to find the best treatment for Frontal fibrosing alopecia.